Pole Star

Pole Star Therapeutics is a Japanese biotechnology company specializing in the discovery and development of drugs targeting RNA-binding proteins (RBPs). The company leverages a proprietary platform to identify small molecules and oligonucleotides that modulate RBP activity, which plays a critical role in post-transcriptional gene regulation. Their primary focus is on the Musashi family of proteins (MSI1 and MSI2), which are implicated in various cancers and neurodegenerative disorders. By targeting these previously undruggable proteins, Pole Star aims to develop first-in-class therapies for high-unmet-need conditions like glioblastoma and Alzheimer's disease. The company is currently in the pre-clinical stage, advancing several programs toward IND-enabling studies.